About the Company
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $HTBX News
Heat Biologics Takes Beating After Pricing $12 Million Stock Offering
Heat Biologics Inc. nosedived after the Durham, North Carolina-based biopharmaceutical company filed for a share offering pricing expected to hit $12 million. Heat Biologics Inc. nosedived after ...
Heat Biologics Announces Research Collaboration with University of Miami to Develop Vaccine Designed to Protect Against COVID-19 Coronavirus
2020 / Heat Biologics, Inc. (HTBX), a clinical-stage biopharmaceutical company specialized in the development of therapeutic vaccines, announced today a strategic collaboration with the University ...
Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters
Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple ...
Heat Biologics, Inc. Submits Revised Protocol to FDA for Phase 2 Clinical Study of HS-110 for the Treatment of Non-Small Cell Lung Cancer
CHAPEL HILL, NC--(Marketwired - Mar 19, 2014) - Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced ...
Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110
Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced promising ...
HCWB HCW Biologics Inc.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases.
Scorpius Holdings, Inc. Announces Pricing of Public Offering
About Scorpius Holdings, Inc. Scorpius Holdings Inc. is an integrated ... For Investor Relations Inquiries: Heat Biologics NewsMORE Related Stocks ...
Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock
About Scorpius Holdings, Inc. Scorpius Holdings Inc. is an integrated ... For Investor Relations Inquiries: Heat Biologics NewsMORE Related Stocks ...
ADMA Biologics Inc ADMA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Heat Biologics, Inc. Submits Revised Protocol to FDA for Phase 2 Clinical Study of HS-110 for the Treatment of Non-Small Cell Lung Cancer
CHAPEL HILL, NC--(Marketwired - Mar 19, 2014) - Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies ...
Loading the latest forecasts...